Actinobacillus pleuropneumoniae

Actinobacillus pleuropneumoniae (APP) is a highly contagious respiratory disease in pigs responsible for major economic losses in swine industry with worldwide distribution. Current solutions with commercially available vaccines, antibiotic treatments and management measures are not solving the problem. With the growing emergence of antibiotic resistance and rising consumer demands concerning food safety, vaccination to prevent APP is of increasing relevance. There is an industrial need for an improved vaccine: a safe and efficient vaccine that offers complete protection against all serotypes. Despite all the research performed in the last years such a vaccine has not yet been developed and reached the market.

Our vaccine is a polyvalent vaccine conferring protection against all APP serotypes. Specific sugar moieties of APP are expressed recombinantly on the surface of  vector bacteria.


 

Further disease information

Actinobacillus pleuropneumoniae (APP) causes porcine pleuropneumonia, a disease of economic importance occurring worldwide. APP is classified into >16 different serovars based on the presence of capsular antigens. The prevalence of different serovars varies from country to country. Serological cross-reactivity and cross-protectivity after infection or immunization has been reported to occur between some of the serovars. APP is a highly contagious, often fatal disease. The disease is characterized by hemorrhagic and necrotizing lung lesions in combination with a fibrinous pleuritis. The pathogen’s ability to survive on respiratory epithelia, in tonsils, and in the anaerobic environment of encapsulated sequesters is of epidemiological importance, as it leads to clinically healthy carrier animals. Importantly, pigs surviving the infection may become asymptomatic carries of APP and transmit the disease to healthy animals. APP bacteria are transmitted by aerosol or direct contact with infected pigs, with asymptomatic carriers being a major source for introduction in previously uninfected herds. In addition, wild boars may act as reservoir for the infection of domestic pigs; surveys in hunted wild boars demonstrated a large number of positives among these animals. Currently, vaccination against APP is hampered by the fact that whole-cell bacterial vaccines neither induce complete cross-serotype immunity nor prevent the development of carrier states.

Latest News

  • 25 January 2017

    Malcisbo has been selected as emerging company to present at the Animal Health Investment Forum in London (Feb 2017)

  • 21 December 2016

    Malcisbo participates in a CTI-funded research project on the development of a vaccine against APP.

  • 29 February 2016

    Collaboration with a pharma company

    R&D collaboration with a pharma company targeting our Campylobacter vaccine.